A team of investigators conducted a cross-sectional study to compare CSF biomarker patterns in Down syndrome compared with those of autosomal dominant Alzheimer disease mutation carriers.
The researchers sought to understand the prognostic value of tau positron emission tomography for predicting cognitive decline across the clinical spectrum of Alzheimer disease.
The researchers conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with dominantly inherited Alzheimer disease across asymptomatic and symptomatic disease stages.
The researchers’ objective was to assess the neuroimaging features of patients with cerebral amyloid angiopathy, or CAA, with and without objective memory impairment using tau PET imaging.
Using transcriptional profiling of mouse meningeal lymphatic endothelial cells, microglia and brain blood endothelial cells, the researchers showed that meningeal lymphatic function is coupled to microglia and brain vascular activation in Alzheimer disease.
The study researchers used deep whole-genome sequencing (WGS) to search for novel AD variants in 2247 individuals from 605 multiplex AD families from the National Institute on Mental Health and the National Institute on Aging (NIA) Alzheimer’s Disease Sequencing Project `data sets.
